Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma - Trial NCT06129955
Access comprehensive clinical trial information for NCT06129955 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 47 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 2
Nov 11, 2023
Dec 31, 2025
Primary Outcome
ORR
Summary
Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it
 eventually enables the successful and safe implementation of partial nephrectomy in patients
 with localized renal cancer, who have indications for nephron-sparing surgery but face
 significant difficulty in kidney preservation (T1b with an endophytic component ≥75% or T2).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06129955
Non-Device Trial